SAN FRANCISCO, July 23 /PRNewswire-FirstCall/ --

    What:      Wednesday, August 6, 2003 @ 2:00 p.m. Pacific Time
               (5:00 p.m. Eastern Time)

    Where:     www.exelixis.com 

How: Visit the Webcast link at the Company's website at www.exelixis.com to listen to the live broadcast on the day of the event. An archive will also be available at www.exelixis.com until August 20, 2003.

    Contact:   Jane Green
               Vice President, Corporate Communications
               650-837-7579
               jmgreen@exelixis.com 

Exelixis, Inc. (Nasdaq: EXEL) is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics, with a focus in the area of oncology. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline and Bristol-Myers Squibb. The company has also established agricultural research collaborations with Bayer CropScience, Dow Agrosciences and Renessen. Other partners include Merck, Schering-Plough Research Institute, Cytokinetics, Elan and Scios. For more information, please visit the company's web site at www.exelixis.com.

SOURCE  Exelixis, Inc.
    -0-                             07/23/2003
    /CONTACT:  Jane Green, Vice President, Corporate Communications of
Exelixis, Inc., +1-650-837-7579, or jmgreen@exelixis.com/
    /Web site:  http://www.exelixis.com/
    (EXEL)

CO:  Exelixis, Inc.
ST:  California
IN:  HEA MTC BIO
SU:  CCA



KG-GF 
-- SFW016A --
2130 08/06/2003 07:45 EDT http://www.prnewswire.com